CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights
Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Andrew Garton(NewYork–Presbyterian Hospital), Nitin Jain(Parul University), Rossana Kazemimood(University of Rochester Medical Center), Julianne Smith(Case Western Reserve University), Mónica L. Guzmán(NewYork–Presbyterian Hospital), Tianyu Cai(Southwest University of Science and Technology), R. Eric Davis(The University of Texas MD Anderson Cancer Center), Nathaniel R. Wilson(The University of Texas Health Science Center at Houston), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Jayastu Senapati(The University of Texas MD Anderson Cancer Center), Joseph D. Khoury(University of Nebraska Medical Center), Minas P. Economides(NYU Langone Health), Mayumi Sugita(Cornell University), Mark G. Frattini(Presbyterian Hospital), Gail J. Roboz(Cornell University)
Cited by 18
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k